Aurealis Therapeutics, a Swiss-Finnish clinical-stage synthetic biology company developing bacteria-based multi-target cell and gene therapies for chronic wounds and cancer, is making remarkable advances in the field with its 4-in-1 technology platform. Director of Genetic Engineering & Manufacturing, Igor Mierau, showcased the company’s research and results at the 14th International Symposium on Lactic Acid Bacteria, held from August 27-31 at Hotel Zuiderduin in Egmond aan Zee, the Netherlands.
During the symposium, Igor presented a poster titled Multi-target bacterial gene therapy for chronic wounds and cancer. This posted summarized the promising outcomes of Aurealis Therapeutics’ phase 1 clinical trial on Diabetic Foot Ulcers (DFUs) and introduced the pioneering in vivo results of a multi-target approach to ovarian cancer.
“I was happy to share our advancements in gene therapies for chronic wounds and cancer with fellow scientists,” expressed Igor Mierau. “Our research demonstrates how Aurealis multi-target products can address complex, multi-factorial diseases, as evidenced by the positive outcomes of our clinical trial on DFUs with AUP-16 and the pre-clinical results in treating ovarian cancer with AUP-55.”
The digital version of Aurealis Therapeutics’ poster can be accessed from the link below:
View the poster: Multi-target bacterial gene therapy for chronic wounds and cancer.
About Aurealis Therapeutics
Aurealis Therapeutics AG is a Swiss-Finnish clinical-stage synthetic biology company creating bacteria-based multi-factor cell and gene therapies for chronic wounds and cancer. The company’s lead clinical assets are the first-in-class four-in-one cell and gene therapies AUP-16 for chronic wounds and AUP-55 for cancers. Aurealis therapies are based on proprietary technology involving genetically engineered Lactococcus Cremoris acting as millions of small immune-activating bioreactors producing multiple human therapeutic proteins (cytokines, growth factors, antibody fragments) to effectively and safely re-educate the distorted host immune microenvironment to a proper state.
For more information:
Laurent Décory, COO
Email: laurent@aurealistherapeutics.com
